Nxera Pharma Co., Ltd. (TYO: 4565)
Japan flag Japan · Delayed Price · Currency is JPY
1,202.00
+8.00 (0.67%)
Nov 12, 2024, 3:40 PM JST

Nxera Pharma Statistics

Total Valuation

Nxera Pharma has a market cap or net worth of JPY 108.06 billion. The enterprise value is 128.60 billion.

Market Cap 108.06B
Enterprise Value 128.60B

Important Dates

The last earnings date was Friday, November 1, 2024.

Earnings Date Nov 1, 2024
Ex-Dividend Date n/a

Share Statistics

Nxera Pharma has 89.90 million shares outstanding. The number of shares has increased by 7.43% in one year.

Current Share Class n/a
Shares Outstanding 89.90M
Shares Change (YoY) +7.43%
Shares Change (QoQ) +0.25%
Owned by Insiders (%) 8.28%
Owned by Institutions (%) 23.99%
Float 66.02M

Valuation Ratios

PE Ratio n/a
Forward PE 39.85
PS Ratio 3.62
PB Ratio 1.59
P/TBV Ratio n/a
P/FCF Ratio 62.03
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 48.38, with an EV/FCF ratio of 73.82.

EV / Earnings -34.65
EV / Sales 4.39
EV / EBITDA 48.38
EV / EBIT n/a
EV / FCF 73.82

Financial Position

The company has a current ratio of 4.01, with a Debt / Equity ratio of 1.02.

Current Ratio 4.01
Quick Ratio 3.73
Debt / Equity 1.02
Debt / EBITDA 26.11
Debt / FCF 39.84
Interest Coverage -0.59

Financial Efficiency

Return on equity (ROE) is -5.90% and return on invested capital (ROIC) is -0.61%.

Return on Equity (ROE) -5.90%
Return on Assets (ROA) -0.54%
Return on Capital (ROIC) -0.61%
Revenue Per Employee 78.70M
Profits Per Employee -9.98M
Employee Count 350
Asset Turnover 0.19
Inventory Turnover 1.93

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -20.51% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -20.51%
50-Day Moving Average 1,263.00
200-Day Moving Average 1,467.93
Relative Strength Index (RSI) 45.62
Average Volume (20 Days) 647,770

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Nxera Pharma had revenue of JPY 29.28 billion and -3.71 billion in losses. Loss per share was -42.09.

Revenue 29.28B
Gross Profit 23.85B
Operating Income -1.31B
Pretax Income -5.11B
Net Income -3.71B
EBITDA 2.66B
EBIT -1.31B
Loss Per Share -42.09
Full Income Statement

Balance Sheet

The company has 48.87 billion in cash and 69.41 billion in debt, giving a net cash position of -20.54 billion or -228.48 per share.

Cash & Cash Equivalents 48.87B
Total Debt 69.41B
Net Cash -20.54B
Net Cash Per Share -228.48
Equity (Book Value) 67.76B
Book Value Per Share 753.72
Working Capital 44.92B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.43 billion and capital expenditures -683.00 million, giving a free cash flow of 1.74 billion.

Operating Cash Flow 2.43B
Capital Expenditures -683.00M
Free Cash Flow 1.74B
FCF Per Share 19.38
Full Cash Flow Statement

Margins

Gross margin is 81.46%, with operating and profit margins of -4.46% and -12.68%.

Gross Margin 81.46%
Operating Margin -4.46%
Pretax Margin -17.45%
Profit Margin -12.68%
EBITDA Margin 9.08%
EBIT Margin -4.46%
FCF Margin 5.95%

Dividends & Yields

Nxera Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -7.43%
Shareholder Yield -7.43%
Earnings Yield -3.50%
FCF Yield 1.61%

Stock Splits

The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.

Last Split Date Jun 27, 2018
Split Type Forward
Split Ratio 4

Scores

Nxera Pharma has an Altman Z-Score of 1.27. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.27
Piotroski F-Score n/a